Patients & Caregivers
Our Commitment
Innovating for You
We are working as urgently as possible to develop new therapies for patients with autoimmune diseases to help them reimagine life. Obexelimab is an investigational drug in clinical development to potentially provide a new, differentiated, therapeutic option for patients with Immunoglobulin G4-Related Disease (IgG4-RD), Multiple Sclerosis (MS), Systemic Lupus Erythematosus (SLE) and warm Autoimmune Hemolytic Anemia (wAIHA).
Our commitment to you is that we will:
-
Work as rapidly and efficiently as possible, because too much is at stake.
-
Honor our values in our interactions.
-
Apply our team’s deep expertise, rigor and passion to advance innovative new therapies.
-
Understand that there is not a one-size-fits-all approach to treating autoimmune diseases.
-
Stay curious and welcome opportunities to connect with you and healthcare professionals to understand your experiences and needs.
-
Stay optimistic about the possibility of delivering innovative therapies based on clinically validated science that could make a significant difference for you.
